Establishment Labs Holdings Inc. (NASDAQ:ESTA) Receives Consensus Rating of "Moderate Buy" from Brokerages

Key Points

• Establishment Labs Holdings Inc. has received a consensus rating of "Moderate Buy" from six brokerages, with five recommending a buy and one holding the stock, with a 12-month price objective averaging $56.50.
• Institutional investors own approximately 72.91% of Establishment Labs' shares, indicating strong institutional interest in the company.
• The company's recent quarterly earnings revealed a reported loss of ($0.57) per share, which was slightly higher than the consensus estimate, but revenue increased by 16.1% year-over-year.

Shares of Establishment Labs Holdings Inc. (NASDAQ:ESTA - Get Free Report) have earned a consensus recommendation of "Moderate Buy" from the six brokerages that are currently covering the firm, Marketbeat.com reports. One research analyst has rated the stock with a hold rating and five have given a buy rating to the company. The average 12-month price objective among brokerages that have issued ratings on the stock in the last year is $56.50.

Several analysts have recently weighed in on ESTA shares. Needham & Company LLC restated a "buy" rating and set a $48.00 target price on shares of Establishment Labs in a research note on Friday, June 13th. Wall Street Zen lowered Establishment Labs from a "hold" rating to a "sell" rating in a research note on Saturday, August 16th. Canaccord Genuity Group initiated coverage on Establishment Labs in a research report on Wednesday, August 20th. They issued a "buy" rating and a $60.00 target price on the stock. Citigroup raised their price target on shares of Establishment Labs from $38.00 to $47.00 and gave the stock a "neutral" rating in a research report on Wednesday, July 9th. Finally, BTIG Research initiated coverage on shares of Establishment Labs in a report on Friday, May 16th. They issued a "buy" rating and a $62.00 price target on the stock.

Institutional Trading of Establishment Labs

Several institutional investors and hedge funds have recently bought and sold shares of ESTA. ANTIPODES PARTNERS Ltd acquired a new position in shares of Establishment Labs in the 1st quarter worth approximately $81,000. Osaic Holdings Inc. boosted its holdings in Establishment Labs by 900.0% in the second quarter. Osaic Holdings Inc. now owns 2,000 shares of the company's stock worth $85,000 after purchasing an additional 1,800 shares during the period. CWM LLC increased its stake in Establishment Labs by 45.9% during the second quarter. CWM LLC now owns 2,182 shares of the company's stock valued at $93,000 after purchasing an additional 686 shares during the last quarter. Elevation Point Wealth Partners LLC acquired a new stake in shares of Establishment Labs during the first quarter worth $207,000. Finally, Patriot Financial Group Insurance Agency LLC acquired a new stake in shares of Establishment Labs during the first quarter worth $234,000. Institutional investors and hedge funds own 72.91% of the company's stock.

Establishment Labs Price Performance

Shares of NASDAQ ESTA opened at $37.93 on Thursday. The company has a debt-to-equity ratio of 9.71, a current ratio of 2.84 and a quick ratio of 1.67. Establishment Labs has a 1-year low of $26.56 and a 1-year high of $50.85. The company has a market capitalization of $1.10 billion, a price-to-earnings ratio of -12.44 and a beta of 0.85. The business has a 50-day moving average of $41.10 and a 200-day moving average of $37.98.

Establishment Labs (NASDAQ:ESTA - Get Free Report) last released its quarterly earnings results on Thursday, August 7th. The company reported ($0.57) EPS for the quarter, missing the consensus estimate of ($0.54) by ($0.03). The company had revenue of $51.30 million for the quarter, compared to analyst estimates of $50.80 million. Establishment Labs had a negative return on equity of 224.34% and a negative net margin of 49.89%.The business's revenue was up 16.1% on a year-over-year basis. During the same period last year, the firm posted ($0.62) earnings per share. Establishment Labs has set its FY 2025 guidance at EPS. On average, equities analysts anticipate that Establishment Labs will post -2.41 EPS for the current fiscal year.

About Establishment Labs

Establishment Labs Holdings Inc, a medical technology company, manufactures and markets medical devices for aesthetic and reconstructive plastic surgery. The company primarily offers silicone gel-filled breast implants under the Motiva Implants brand. It also provides Motiva Ergonomix and Motiva Ergonomix2 gravity sensitive round soft silicone-gel-filled breast implants; and Motiva Flora Tissue Expander, a breast tissue expander.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.